Inventor
YEAGER JAMES L
US21 patents
⚠️ This page may combine multiple inventors who share the name “YEAGER JAMES L”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
NEXMED HOLDINGS INC
10 patentsUS6693135B2Feb 17, 2004
Prostaglandin compositions and methods of treatment for male erectile dysfunction
NEXMED HOLDINGS INC67 citations95
US6486207B2Nov 26, 2002
Compositions and methods for amelioration of human female sexual dysfunction
NEXMED HOLDINGS INC57 citations95
US6323241B1Nov 27, 2001
Prostaglandin compositions and methods of treatment for male erectile dysfunction
NEXMED HOLDINGS INC65 citations95
US7105571B2Sep 12, 2006
Prostaglandin compositions and methods of treatment for male erectile dysfunction
NEXMED HOLDINGS INC28 citations91
US6825234B2Nov 30, 2004
Compositions and methods for amelioration of human female sexual dysfunction
NEXMED HOLDINGS INC35 citations91
US6414028B1Jul 2, 2002
Topical compositions containing prostaglandin E1
NEXMED HOLDINGS INC45 citations91
US6224573B1May 1, 2001
Medicament dispenser
NEXMED HOLDINGS INC74 citations91
US9066854B2Jun 30, 2015
Alprostadil and dyclonine for treatment of premature ejaculation
NEXMED HOLDINGS INC2 citations61
US9060929B2Jun 23, 2015
Alprostadil for treatment of premature ejaculation
NEXMED HOLDINGS INC1 citations61
US9056044B2Jun 16, 2015
Alprostadil and lidocaine treatment of premature ejaculation
NEXMED HOLDINGS INC2 citations61
MEZZION PHARMA CO LTD
4 patentsUS10653698B2May 19, 2020
Methods of improving myocardial performance in Fontan patients using udenafil compositions
MEZZION PHARMA CO LTD5 citations79
US10137128B2Nov 27, 2018
Methods of improving myocardial performance in fontan patients using udenafil compositions
MEZZION PHARMA CO LTD7 citations79
US12048701B2Jul 30, 2024
Methods of improving myocardial performance in Fontan patients using udenafil compositions
MEZZION PHARMA CO LTD1 citations68
US12576081B2Mar 17, 2026
Methods and compositions for improving exercise performance, single ventricular performance, cardiac output and myocardial performance index (MPI) in single ventricular heart disease, using udenafil compositions
MEZZION PHARMA CO LTD0 citations57